Gilead Sciences' Kite Pharma unit made its name developing autologous CAR-T treatments made from a patient’s own cells. Now, the subsidiary is making another big play in off-the-shelf treatments ...

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite w ...

RELATED: Gilead's Kite bags second CAR-T okay with Tecartus nod in mantle cell lymphoma Previous research has linked prior use of Amgen’s CD3-CD19 bispecific T-cell engager Blincyto to a reduced ...

With today’s announcement, and through a variety of optimization efforts across Kite’s global CAR T-cell therapy manufacturing network, Kite estimates network capacity will be increased by 50% ...

They created the first CAR-T for non-Hodgkin lymphoma, and now they're working on the next chapter. | After selling Kite Pharma off to Gilead for $11.9 billion, former executives Arie Belldegrun ...

Gilead's Kite wins FDA nod for new CAR-T manufacturing process to speed up Yescarta turnaround. By Angus Liu Jan 30, 2024 8:39am. Gilead Sciences Kite Pharma CAR-T cell therapy ...

Gilead already had close ties with Tmunity as one of the investors in the biotech’s $100 million Series A round of financing in 2018.The acquisition agreement calls for Gilead’s Kite to ...

Kite, a Gilead Company, will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the ...

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

In June 2016, Cell Design Labs and what was then independently owned Kite Pharma launched an up-to-$67.5 million collaboration to develop next-generation, precision-controlled CAR-T immunotherapy ...

Kite, a Gilead company GLD, announced that the Food & Drug Administration granted accelerated approval to Tecartus, a CAR T cell therapy for the treatment of adult patients with mantle cell lymphoma.

Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.